ATE141051T1 - Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie - Google Patents

Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie

Info

Publication number
ATE141051T1
ATE141051T1 AT93302513T AT93302513T ATE141051T1 AT E141051 T1 ATE141051 T1 AT E141051T1 AT 93302513 T AT93302513 T AT 93302513T AT 93302513 T AT93302513 T AT 93302513T AT E141051 T1 ATE141051 T1 AT E141051T1
Authority
AT
Austria
Prior art keywords
melatonin
treatment
beneficient
production
bph
Prior art date
Application number
AT93302513T
Other languages
English (en)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Application granted granted Critical
Publication of ATE141051T1 publication Critical patent/ATE141051T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93302513T 1992-04-07 1993-03-31 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie ATE141051T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86468492A 1992-04-07 1992-04-07

Publications (1)

Publication Number Publication Date
ATE141051T1 true ATE141051T1 (de) 1996-08-15

Family

ID=25343832

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93302513T ATE141051T1 (de) 1992-04-07 1993-03-31 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie

Country Status (11)

Country Link
US (2) US5750557A (de)
EP (1) EP0565296B1 (de)
JP (1) JPH0640939A (de)
AT (1) ATE141051T1 (de)
DE (1) DE69303919T2 (de)
DK (1) DK0565296T3 (de)
ES (1) ES2090861T3 (de)
GR (1) GR3021258T3 (de)
HK (1) HK1006681A1 (de)
IL (1) IL105240A (de)
SG (1) SG41955A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09511334A (ja) * 1994-03-30 1997-11-11 チバ−ガイギー アクチェンゲゼルシャフト Ｒｚｒ受容体ファミリーを用いるスクリーニング方法
EP0748627A3 (de) * 1995-06-14 1997-05-21 Lilly Co Eli Melatoninagonisten zur Behandlung von gutartigen Hyperplasieformen der Prostata
NZ500217A (en) * 1997-04-07 2001-11-30 American Home Prod Estra-5(10), 7-dienes for treating estrogen deficiency, osteoporosis and free radical induced disease states
DK1272177T3 (da) * 2000-01-05 2007-08-06 Neurim Pharma 1991 Fremgangsmåde og formulering til behandling af resistens over for antihypertensiva og forbundne tilstande
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
EP1715742A4 (de) * 2004-02-20 2009-06-17 Lifescape Biosciences Inc Zusammensetzungen und verfahren für die schlafregulierung
AU2008228903B2 (en) 2007-03-19 2013-03-07 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin B12
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
ES2828034T3 (es) 2016-10-31 2021-05-25 Neurim Pharma 1991 Minicomprimidos de melatonina y método de fabricación de los mismos
CN114982720B (zh) * 2022-07-26 2024-02-13 贵州省人民医院 一种建立小鼠或大鼠雌雄激素失调型前列腺增生模型的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
EP0330652A1 (de) * 1987-02-13 1989-09-06 GRAZIOSI, Maurizio System um schuhunterteile atoxisch zu machen
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
GB8727099D0 (en) * 1987-11-19 1987-12-23 Cellena Cell Eng A G Compositions containing melantonin/homologues
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
IN171596B (de) 1989-06-27 1992-11-21 Cohen Michael
DK0518468T3 (da) 1991-05-09 2000-01-31 Neurim Pharma 1991 Melatoninholdige sammensætninger
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma

Also Published As

Publication number Publication date
GR3021258T3 (en) 1997-01-31
IL105240A0 (en) 1993-07-08
EP0565296B1 (de) 1996-08-07
DE69303919D1 (de) 1996-09-12
DK0565296T3 (da) 1996-12-09
ES2090861T3 (es) 1996-10-16
JPH0640939A (ja) 1994-02-15
SG41955A1 (en) 1997-08-15
US6048888A (en) 2000-04-11
DE69303919T2 (de) 1997-01-30
EP0565296A1 (de) 1993-10-13
IL105240A (en) 1999-04-11
US5750557A (en) 1998-05-12
HK1006681A1 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
ATE141051T1 (de) Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
HUT60138A (en) Process for producing combination compositions suitable for preventing and/or treating benign prostatic hyperplasia
ATE430568T1 (de) Verfahren und zusammensetzungen zur vorbeugung oder behandlung von atherosclerose, restenose und zusammenhängenden erkrankungen
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DE69424537T2 (de) Therapeutischer wirkstoff zur behandlung von melanomen
ATE198706T1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE59508360D1 (de) Liposomal verkapseltes taxol, seine herstellung und seine verwendung
EP0646007A1 (de) NEUE DELTA-17 UND DELTA-20 UNGESÄTIGTE UND GESATIGTE 17--g(b)-SUBSTITUIERTE-4-AZA-5-g(a)-ANDROSTAN-3-ON VERBINDUNGEN ALS INHIBITOREN VON 5-ALPHA-REDUCTASE.
ATE218860T1 (de) Verwendung von 3,4-diphenylchromanen zur herstellung eines arzneimittels zur behandlung bzw. vorbeugung des prostatakarzinoms
IT1270993B (it) Derivati chinzolilamminici attivi come alfa-antagonisti
DE60313603D1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
ATE247968T1 (de) Kombination von dehydroepiandrosteron und aromatasehemmern und verwendung dieser kombination zur herstellung eines arzneimittels zur behandlung eines relativen und absoluten androgenmangels beim mann
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
DE3685052D1 (de) Linolensaeuren enthaltende pharmazeutische und diaet-zusammensetzungen zur behandlung von gutartiger prostatahypertrophie.
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE69424563D1 (de) Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
BR9203266A (pt) Composto,formulacao farmaceutica,processo para inibir 5alfa-reductase,processos para tratar hiperplasia benigna da prostata,seborreia e alopecia androgenica
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
HUP9901139A3 (en) Use of melatonin agonists for producing pharmaceutical compositions suitable for treating benign prostatic hyperplasia
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee